RSS-Feed abonnieren
DOI: 10.1055/s-0029-1220781
Warfarin-Associated Fetal Intracranial Hemorrhage in Woman with Mitral Valve Replacements: A Case Report
Publikationsverlauf
Publikationsdatum:
29. April 2009 (online)
![](https://www.thieme-connect.de/media/ajp/200908/lookinside/thumbnails/10.1055-s-0029-1220781-1.jpg)
ABSTRACT
Warfarin-associated fetal hemorrhage is a fatal event. We report the case of a 39-year-old woman who had been taking warfarin for 23 years since undergoing mitral valve replacement. Thereafter, when she was found to be pregnant, the medication was switched to heparin from 6 to 21 weeks of gestation. Following this, she was prescribed oral warfarin again (3.5 mg per day), with a strict control of prothrombin time/international normalized ratio (PT/INR). At 23 weeks of gestation, fetal intracranial hemorrhage occurred because of maternal exposure to warfarin. Maternal PT/INR does not correlate well with the activity of warfarin in the fetus and currently, there is no direct way to prevent fetal intracranial hemorrhage. Hence, further research on the optimal coagulation therapy in pregnant women with valve replacement should be encouraged.
KEYWORDS
Warfarin - fetal intracranial hemorrhage - mitral valve replacement - heparin
REFERENCES
- 1 Sbarouni E, Oakley C M. Outcome of pregnancy in women with valve prostheses. Br Heart J. 1994; 71 196-201
- 2 Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000; 160 191-196
- 3 Sadler L, McCowan L, White H, Stewart L, Bracken M, North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG. 2000; 107 245-253
- 4 Hall J G, Pauli R M, Wilson K M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980; 68 122-140
- 5 Bajoria R, Soorana S R, Contractor S F. Differential binding of warfarin to maternal, foetal and nonpregnant sera and its clinical implications. J Pharm Pharmacol. 1996; 48 486-491
- 6 Irollo B, Dang Vu B, Nguyen Dai D, Yonger J. Dissociation and association rate constants changes following bilirubin binding affinity decreases. Dev Pharmacol Ther. 1987; 10 436-442
- 7 Reverdiau-Moalic P, Delahousse B, Body G et al.. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood. 1996; 88 900-906
- 8 Cotrufo M, De Feo M, De Santo L S et al.. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002; 99 35-40
- 9 Lee H C, Cho S Y, Lee H J, Kim C J, Park J S, Chi J G. Warfarin-associated fetal intracranial hemorrhage: a case report. J Korean Med Sci. 2003; 18 764-767
- 10 Robinson M J, Cameron M D, Smith M F, Ayers A B. Fetal subdural haemorrhages presenting as hydrocephalus. Br Med J. 1980; 281 35
- 11 Ville Y, Jenkins E, Shearer M J et al.. Fetal intraventricular hemorrhage and maternal warfarin. Lancet. 1993; 341 1211
- 12 Oswal K, Agarwal A. Warfarin-induced fetal intracranial subdural hematoma. J Clin Ultrasound. 2008; 36 451-453
- 13 Matsuda Y, Hashiguchi K, Akizawa Y, Saito R, Ohta H. A case of fetal subdural hematoma at 31 weeks of gestation in a woman on warfarin therapy after Cabrol's operation. Fetal Diagn Ther. 2003; 18 252-254
- 14 Porreco R P, McDuffie Jr R S, Peek S D. Fixed mini-dose warfarin for prophylaxis of thromboembolic disease in pregnancy. A safe alternative for the fetus?. Obstet Gynecol. 1993; 81 806-807
- 15 Vitale N, De Feo M, Cotrufo M. Letter to the Editor. J Am Coll Cardiol. 2000; 35 1365-1366
- 16 Nassar A H, Hobeika E M, Abd Essamad H M, Taher A, Khalil A M, Usta I M. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol. 2004; 191 1009-1013
Yoichi AokiM.D.
Department of Obstetrics and Gynecology, Faculty of Medicine, University of the Ryukyus
207 Uehara, Nishihara, Okinawa 903-0215, Japan
eMail: yoichi@med.u-ryukyu.ac.jp